According to a recent LinkedIn post from Cleerly, new data from the INVICTUS registry suggest the company’s AI-based quantitative coronary CT (AI-QCT) technology shows 94.4% agreement with intravascular ultrasound (IVUS), an invasive gold-standard modality, for coronary plaque quantification across 17 centers. The post frames this result as a scientific milestone toward more accessible and less invasive plaque characterization, citing Cleerly founder James Min, M.D.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights that achieving high concordance with IVUS may support AI-QCT as a clinically credible alternative for plaque assessment in routine cardiac imaging workflows. For investors, such validation data could strengthen Cleerly’s value proposition with hospitals, cardiology practices, and payers, potentially supporting adoption, reimbursement discussions, and long-term recurring revenue models.
The post also suggests that robust multi-center registry evidence could differentiate Cleerly in a competitive cardiac imaging and AI diagnostics landscape. If regulators, guideline bodies, and large provider networks view these results favorably, Cleerly may gain an advantage in securing strategic partnerships, scaling deployments, and reinforcing its positioning around the broader goal of reducing heart attacks.
While the LinkedIn content links to a press release for more detailed results, it does not provide financial metrics or commercial contracts tied to this dataset. However, ongoing evidence generation of this type is often a precursor to commercial traction, and investors may interpret the registry data as an incremental de-risking of Cleerly’s clinical technology and a supportive signal for future market penetration.